Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

AIM Company Profile and Key Details

AMEX : AIM

AIM ImmunoTech

$3.05
-0.1-3.18%
At Close 4:00 PM
$3.05
−0.14-4.56%
Pre-Market 08:30 PM
63.57
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

AIM ImmunoTech Inc. (AIM) stock declined over -3.17%, trading at $3.05 on AMEX, down from the previous close of $3.15. The stock opened at $3.16, fluctuating between $3.02 and $3.39 in the recent session.

Stock Snapshot

3.15
Prev. Close
2.33M
Market Cap
3.02
Day Low
-0.13
P/E Ratio
-24
EPS (TTM)
-0.45
Cash Flow per Share
3.16
Open
764.19K
Number of Shares
3.39
Day High
95.49%
Free Float in %
0.21
Book Value
475.08K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jul 30, 20253.163.393.003.05472.27K
Jul 29, 20253.503.692.923.152.6M
Jul 28, 202518.9820.356.717.204.46M
Jul 25, 20258.238.407.908.403.42K
Jul 24, 20258.558.698.218.413.78K
Jul 23, 20258.218.558.218.551.69K
Jul 22, 20258.979.118.008.4015.9K
Jul 21, 20258.809.008.808.811.67K
Jul 18, 20258.929.258.509.258.59K
Jul 17, 20258.809.008.238.656.48K
Jul 16, 20258.809.108.308.8513.36K
Jul 15, 20258.959.398.798.798.65K
Jul 14, 20259.259.669.109.153.45K
Jul 11, 20258.879.478.879.0913.64K
Jul 10, 20259.509.509.199.366K
Jul 09, 20259.589.598.889.274.38K
Jul 08, 20259.189.398.869.102.5K
Jul 07, 20258.859.178.858.851.77K
Jul 03, 20259.069.518.858.853.65K
Jul 02, 20258.849.348.849.171.79K

Contact Details

Ocala, FL 34473

United States

https://www.aimimmuno.com352 448 7797

About Company

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Company Information

Employees21
Beta0.32
Sales or Revenue$202.00K
5Y Sales Change%-0.989%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current AIM ImmunoTech Inc. (AIM) stock price?
AIM ImmunoTech Inc. (AMEX: AIM) stock price is $3.05 in the last trading session. During the trading session, AIM stock reached the peak price of $3.39 while $3.02 was the lowest point it dropped to. The percentage change in AIM stock occurred in the recent session was -3.17% while the dollar amount for the price change in AIM stock was -$0.10.
AIM's industry and sector of operation?
The AMEX listed AIM is part of Biotechnology industry that operates in the broader Healthcare sector. AIM ImmunoTech Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of AIM?
Dr. Carol A. Smith
Chief Manufacturing Officer & Deputy Chief Scientific Officer
Dr. Christopher McAleer Ph.D.
Scientific Officer
Dr. David R. Strayer M.D.
Chief Scientific Officer & Medical Director
Ann Marie E. Coverly
Director of Admin. & HR and Deputy Investor Relations Coordinator
Jodie Pelz
Controller
Dr. Ralph Christopher Cavalli Ph.D.
Vice President of QC & Manufacturing
Mr. Thomas K. Equels Esq., J.D., M.S.
Executive Vice Chairman, Chief Executive Officer & Pres
Mr. Peter W. Rodino III, Esq., J.D.
Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec.
How AIM did perform over past 52-week?
AIM's closing price is 4.45% higher than its 52-week low of $2.92 where as its distance from 52-week high of $40.00 is -92.38%.
How many employees does AIM have?
Number of AIM employees currently stands at 21.
Link for AIM official website?
Official Website of AIM is: https://www.aimimmuno.com
How do I contact AIM?
AIM could be contacted at phone 352 448 7797 and can also be accessed through its website. AIM operates from 2117 SW Highway 484, Ocala, FL 34473, United States.
How many shares of AIM are traded daily?
AIM stock volume for the day was 475.08K shares. The average number of AIM shares traded daily for last 3 months was 130.75K.
What is the market cap of AIM currently?
The market value of AIM currently stands at $2.33M with its latest stock price at $3.05 and 764.19K of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings Calendar
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph